PMID- 30530052
OWN - NLM
STAT- MEDLINE
DCOM- 20190503
LR  - 20190503
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 66
DP  - 2019 Jan
TI  - Therapeutic targets of vitamin C on liver injury and associated biological 
      mechanisms: A study of network pharmacology.
PG  - 383-387
LID - S1567-5769(18)30720-3 [pii]
LID - 10.1016/j.intimp.2018.11.048 [doi]
AB  - In our previous studies, vitamin C (VC) exerts potent pharmacological activities 
      against liver injury (LI). Therefore, this report was designed to use network 
      pharmacology-based strategy to predict therapeutic targets of VC against LI, and 
      further to investigate the pharmacological molecular mechanisms. Pathological 
      targets of LI were identified, followed by acquisition of verified targets of VC. 
      After constructing target-functional protein interaction network of VC against 
      LI, the core therapeutic targets of VC against LI were obtained. Further, 
      biological function and pathway enrichment analyses were performed on core 
      therapeutic targets to evaluate the biological processes and key signaling 
      pathways of VC against LI. As revealed in network pharmacology assays, 6 key 
      therapeutic targets for VC against LI were identified, showing tumor necrosis 
      factor (TNF), nuclear factor-kappa-B p65 (RELA), nuclear factor-kappa-B p105 
      (NFKB1), TNF receptor-associated factor 2 (TRAF2), interleukin 6 (IL-6) and 
      interleukin 1 beta (IL1B). On the basis of data analyses from DAVID database and 
      omicshare cloud platform, bio-functional enrichment assays showed that the 
      therapeutic effects of VC against LI were closely associated with regulating 
      inflammatory reaction and apoptosis. Further, pathway enrichment analysis 
      indicated the anti-LI benefits of VC were principally implicated in regulating 
      the top 20 signaling pathways, such as inflammation-associated TNF signaling 
      pathway, NF-kappaB signaling pathway. Taken together, the bioinformatics data 
      elucidate that anti-LI pharmacological activities of VC may be predominantly 
      related to inhibition of inflammatory stress, contributing to suppression of LI 
      development. These resultant findings highlight the predicted therapeutic targets 
      may be potential biomarkers for anti-LI.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Su, Min
AU  - Su M
AD  - Faculty of Basic Medicine, Guilin Medical University, Guilin 541004, PR China.
FAU - Guo, Chao
AU  - Guo C
AD  - Department of Pharmacy, Guigang City People's Hospital, The Eighth Affiliated 
      Hospital of Guangxi Medical University, Guigang 537100, Guangxi, PR China.
FAU - Liu, Meizhen
AU  - Liu M
AD  - College of Pharmacy, Guangxi Medical University, Guangxi, Nanning 530021, PR 
      China.
FAU - Liang, Xiaoliu
AU  - Liang X
AD  - College of Pharmacy, Guangxi Medical University, Guangxi, Nanning 530021, PR 
      China.
FAU - Yang, Bin
AU  - Yang B
AD  - College of Pharmacy, Guangxi Medical University, Guangxi, Nanning 530021, PR 
      China. Electronic address: gxmu_yangbin@126.com.
LA  - eng
PT  - Journal Article
DEP - 20181205
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 0 (NF-kappa B)
RN  - 0 (TNF Receptor-Associated Factor 2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - PQ6CK8PD0R (Ascorbic Acid)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*pharmacology
MH  - Ascorbic Acid/*pharmacology
MH  - Humans
MH  - Inflammation/*drug therapy
MH  - Interleukin-1beta/metabolism
MH  - Interleukin-6/metabolism
MH  - Liver Diseases/*drug therapy
MH  - Molecular Targeted Therapy
MH  - NF-kappa B/metabolism
MH  - Pharmacology/*trends
MH  - *Protein Interaction Maps
MH  - Signal Transduction
MH  - TNF Receptor-Associated Factor 2/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
OTO - NOTNLM
OT  - Inflammation
OT  - Liver injury
OT  - Network pharmacology
OT  - Target
OT  - Vitamin C
EDAT- 2018/12/12 06:00
MHDA- 2019/05/06 06:00
CRDT- 2018/12/12 06:00
PHST- 2018/09/22 00:00 [received]
PHST- 2018/11/23 00:00 [revised]
PHST- 2018/11/27 00:00 [accepted]
PHST- 2018/12/12 06:00 [pubmed]
PHST- 2019/05/06 06:00 [medline]
PHST- 2018/12/12 06:00 [entrez]
AID - S1567-5769(18)30720-3 [pii]
AID - 10.1016/j.intimp.2018.11.048 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2019 Jan;66:383-387. doi: 10.1016/j.intimp.2018.11.048. Epub 
      2018 Dec 5.